title: Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
abstract: Recurrent glioblastoma multiforme is a lethal disease with currently available treatment options having a limited impact on outcome. In this article, current and novel therapeutic approaches in the treatment of recurrent glioblastoma multiforme, including chemotherapy, targeted molecular agents, virotherapy/gene therapy and immunotherapy and challenges in developing novel therapeutic agents for glioblastoma multiforme will be discussed.
authors.affiliation: Mayo Clinic, Department of Oncology, 200 1st Str SW, Rochester, MN 55905, USA. simpson.lijo@mayo.edu
authors.forename: Lijo
authors.initials: L
authors.lastname: Simpson
authors.forename: Evanthia
authors.initials: E
authors.lastname: Galanis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D004358:Drug Therapy / Q000639:trends; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods; D005909:Glioblastoma / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D006133:Growth Substances / Q000502:physiology; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D008954:Models, Biological; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D006133:Growth Substances; D056572:Histone Deacetylase Inhibitors